Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Haleon Plc on November 1, 2024, for the month of November 2024. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). The filing primarily discloses the company's total voting rights and capital structure as of October 31, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on share capital and voting rights.
| Metric | Value |
|---|---|
| Total Ordinary Shares Issued | 9,083,725,919 |
| Share Par Value | £0.01 each |
| Treasury Shares | 30,365,037 |
| Ordinary Shares with Voting Rights | 9,053,360,882 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It serves as a statutory update on the denominator for calculating notifiable interests under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document reiterates the company's purpose to deliver better everyday health with humanity and lists its major brands, including Advil, Sensodyne, Panadol, and Centrum.
Investor Verification Checklist
- Verify the total number of voting shares (9,053,360,882) for compliance with notification thresholds under FCA rules.
- Confirm the number of treasury shares held (30,365,037) to understand the difference between issued and outstanding voting shares.
- Check the company secretary contact (company.secretary@haleon.com) for submitting notifiable interest notifications.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.